Drug Profile


Alternative Names: ACE-011; RAP-011

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation; Indiana University; North Shore-Long Island Jewish Health System; University of Texas M. D. Anderson Cancer Center
  • Class Osteoporosis therapies; Recombinant fusion proteins
  • Mechanism of Action Activin inhibitors; Bone development stimulants; Haemoglobin stimulants; Osteoblast inhibitors; Osteoclast stimulants; Osteogenesis stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia; Beta-thalassaemia; Myelofibrosis; Renal osteodystrophy; Vascular calcification
  • Phase I/II Diamond-Blackfan syndrome
  • No development reported Cancer metastases; Chemotherapy-induced anaemia; Postmenopausal osteoporosis; Sickle cell anaemia

Most Recent Events

  • 01 Mar 2017 Acceleron and Celgene plan a phase II trial for Myelofibrosis (Combination therapy with luspatercept)
  • 05 Dec 2016 Efficacy and adverse events data from a phase II trial in Myelofibrosis presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 08 Nov 2016 Phase-II development is ongoing for Myelofibrosis in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top